Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd

₹ 987 -1.27%
12 Jul - close price
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company[1] Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market.

  • Market Cap 19,392 Cr.
  • Current Price 987
  • High / Low 1,094 / 645
  • Stock P/E 31.6
  • Book Value 245
  • Dividend Yield 1.11 %
  • ROCE 13.1 %
  • ROE 13.3 %
  • Face Value 2.00

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 39.6%

Cons

  • Stock is trading at 4.02 times its book value
  • The company has delivered a poor sales growth of 9.62% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 10.2% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
1,280 1,326 1,292 1,272 1,416 1,262 1,475 1,509 1,406 1,486 1,595 1,631 1,517
960 1,090 1,054 1,030 1,268 1,255 1,244 1,274 1,203 1,287 1,387 1,364 1,257
Operating Profit 320 236 239 242 148 7 231 235 204 199 208 266 260
OPM % 25% 18% 18% 19% 10% 1% 16% 16% 14% 13% 13% 16% 17%
25 2 21 19 10 1 0 0 1 12 10 3 4
Interest 3 2 5 4 7 9 12 15 14 14 16 15 11
Depreciation 51 53 55 56 123 67 68 67 74 66 68 69 69
Profit before tax 292 183 200 201 29 -67 151 154 116 130 135 185 183
Tax % 19% 19% 20% 14% 24% 2% 12% 21% -31% 7% -1% 2% 3%
242 158 164 172 22 -66 133 122 153 121 137 180 178
EPS in Rs 12.75 8.37 8.34 8.74 1.12 -3.35 6.78 6.20 7.76 6.14 6.95 9.18 9.07
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,520 1,863 2,056 3,166 3,105 3,131 3,935 4,606 5,393 5,306 5,653 6,229
1,268 1,506 1,653 2,159 2,490 2,488 3,061 3,383 3,913 4,432 4,970 5,296
Operating Profit 252 358 403 1,007 615 643 874 1,223 1,480 874 682 932
OPM % 17% 19% 20% 32% 20% 21% 22% 27% 27% 16% 12% 15%
4 4 4 7 2 7 9 -39 87 56 -2 28
Interest 15 10 4 5 5 3 18 27 16 18 50 56
Depreciation 35 40 44 72 83 105 115 157 183 287 275 273
Profit before tax 206 311 359 936 529 541 749 1,000 1,368 625 355 632
Tax % 20% 24% 21% 23% 23% 22% 21% 20% 19% 17% 4% 3%
165 236 283 720 403 413 583 801 1,146 521 342 616
EPS in Rs 8.77 12.49 15.01 38.20 21.39 21.89 31.00 43.97 58.33 26.50 17.40 31.33
Dividend Payout % 29% 24% 23% 9% 19% 18% 18% 23% 24% 38% 46% 35%
Compounded Sales Growth
10 Years: 13%
5 Years: 10%
3 Years: 5%
TTM: 10%
Compounded Profit Growth
10 Years: 10%
5 Years: 1%
3 Years: -19%
TTM: 77%
Stock Price CAGR
10 Years: 11%
5 Years: 14%
3 Years: 1%
1 Year: 50%
Return on Equity
10 Years: 20%
5 Years: 16%
3 Years: 10%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 38 38 38 38 38 38 38 38 39 39 39 39
Reserves 465 638 847 1,560 1,865 2,182 2,681 3,182 5,028 5,198 4,331 4,779
187 109 264 114 89 708 1,128 1,747 584 717 722 513
358 432 493 718 698 1,013 931 1,022 1,058 1,167 1,090 1,114
Total Liabilities 1,048 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446
344 397 547 708 799 993 1,158 1,552 1,788 1,798 2,398 2,547
CWIP 32 21 83 93 396 1,010 1,551 1,846 2,183 2,304 601 524
Investments 3 3 2 87 50 42 49 18 236 118 96 93
668 796 1,009 1,541 1,444 1,896 2,019 2,573 2,502 2,902 3,087 3,281
Total Assets 1,048 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
265 240 172 948 329 312 812 449 1,463 552 724 803
-67 -81 -256 -307 -486 -884 -756 -731 -840 -372 -448 -321
-229 -151 87 -224 -129 503 59 155 -597 -217 -262 -438
Net Cash Flow -31 8 3 417 -286 -69 115 -127 26 -37 14 45

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 56 54 64 40 40 61 45 69 24 56 68 60
Inventory Days 143 159 196 266 269 302 356 417 431 406 315 350
Days Payable 129 148 166 264 213 313 237 220 194 178 145 157
Cash Conversion Cycle 70 65 94 42 96 51 164 266 261 283 237 253
Working Capital Days 59 50 71 49 72 93 64 118 94 118 119 114
ROCE % 31% 44% 38% 66% 29% 22% 23% 24% 26% 11% 7% 13%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
69.48% 69.48% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61%
5.52% 5.89% 6.02% 5.94% 5.32% 4.99% 4.55% 4.34% 4.51% 4.52% 4.46% 4.32%
11.42% 11.61% 11.74% 12.15% 12.55% 12.76% 13.32% 13.65% 14.22% 14.51% 15.39% 15.47%
13.58% 13.03% 12.63% 12.30% 12.52% 12.64% 12.53% 12.39% 11.67% 11.36% 10.54% 10.61%
No. of Shareholders 1,23,0591,10,0381,06,4371,01,4571,03,8111,01,86499,52297,60789,55285,21276,56774,829

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls